The antibody profile could potentially be used to improve stratification of patient cohorts in clinical trials or as a point-of-care test to determine whether a patient needs vaccination, Reinhard Hiller, managing director of CPGR, told ProteoMonitor.
The recruitment effort seeks researchers to fill two new positions in metabolic engineering and synthetic biology; two new positions in computational tools and technology development; and two existing positions in chemical, molecular and systems biology, and bioengineering.
CPGR will be developing multiplex protein array-based antibody profiling assays and related bioinformatic analysis methods for the project with the ultimate aim of creating a biomarker signature that can be used for companion diagnostic purposes.
The algorithm, which was developed in collaboration with researchers in the Mathematics of Information Technology and Complex Systems groups at the University of British Columbia and Simon Fraser University, will allow Kinexus to do high-resolution mapping of an estimated 25 million kinase-substrate interactions, said a company official.
Eiger Biopharma licenses Hep C Rx IP from Stanford; TapImmune buys vaccine IP from UBC; Acetylon Pharma closes $7.25M series A to commercialize Dana-Farber, Harvard HDAC inhibitors; EMD Serono and MD Anderson ink clinical trial pact; U of Queensland's IMBcom licenses HGH receptor cell lines to Prolor Biotech